# Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

> **NCT02452528** · PHASE2 · TERMINATED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 4 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ARC-520
- **DRUG:** Placebo
- **DRUG:** Entecavir
- **DRUG:** Tenofovir
- **DRUG:** diphenhydramine

## Key facts

- **NCT ID:** NCT02452528
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Company decision to discontinue trial
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452528, "Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02452528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*